Neogen Corporation
NEOGIn Vitro & In Vivo Diagnostic Substances · Avg daily volume 3.2M · fiscal year ends May$11.96−1.05−8.07%Volume 6.0M+86% vs avg
10-day20-day50-day200-dayRS line vs S&P 500▲ earnings filed, EPS vs a year agoQ1 EPS due in ~2 days
2026-10-06O 13.06 H 13.22 L 11.86 C 11.96 (−8.07%)Vol 6.0M10 12.9620 12.7650 12.02200 10.05RS line 1.535RS rating 89
| FY (May) | EPS $ | Chg | High | Low |
|---|---|---|---|---|
| 2019 | 0.57 | −5% | – | – |
| 2020 | 0.56 | −2% | – | – |
| 2021 | 0.57 | +1% | – | – |
| 2022 | 0.45 | −21% | – | – |
| 2023 | -0.12 | −127% | – | – |
| 2024 | -0.04 | +67% | – | – |
| 2025 | – | – | 19 | 4 |
| 2026 | -0.04 | – | 11 | 5 |
| TTM | -0.03 | 14 | 5 |
Ratings & facts
RS Rating89 ▼2
Days at RS 90+0
Setup checks1 / 3
EPS chg, last qtr–
EPS acceleratingno
Sales chg, last qtr−0%
P/E (last 4 qtrs)–
Mkt cap$2.60B
Off 52-wk high-16.1%
Quarterly earnings
Latest filing: 10-K, 2026-07-30Feb ’24FQ3 ’24
May ’24Q4FQ4 ’24
Aug ’24FQ1 ’25
Nov ’24FQ2 ’25
Feb ’25FQ3 ’25
May ’25Q4FQ4 ’25
Aug ’25FQ1 ’26
Nov ’25FQ2 ’26
Feb ’26FQ3 ’26
May ’26Q4FQ4 ’26
EPS
EPS
−$0.01
−$0.02
−$0.06
–
−$0.05
–
$0.17
−$0.07
−$0.08
−$0.05
% chg
−125%
−167%
−700%
–
−400%
–
+383%
–
−60%
–
Sales
228.8M
236.8M
217.0M
231.3M
221.0M
225.5M
209.2M
224.7M
211.2M
225.3M
% chg
+5%
−2%
−5%
+1%
−3%
−5%
−4%
−3%
−4%
−0%
Filed
04/09
07/30
10/10
01/15
04/09
07/30
10/09
01/08
04/09
07/30
EPS growth ≥ 25%0–25%fallingno comparison
Source: SEC EDGAR 10-Q and 10-K filings, loaded the first time a stock is opened and refreshed daily. Q4 = full year minus the first three quarters. Growth from a loss is measured against the size of the loss (−$1 → $2 = +300%). Analyst estimates are not in EDGAR.